AI Engines For more Details: Perplexity Kagi Labs You
Hyperlipidemia: Ciprofibrate is indicated for the treatment of various forms of hyperlipidemia, including hypercholesterolemia (high levels of cholesterol) and hypertriglyceridemia (high levels of triglycerides). It belongs to a class of medications known as fibric acid derivatives or fibrates, which work by activating peroxisome proliferator-activated receptors (PPARs) in the liver and peripheral tissues. This activation leads to increased lipolysis of triglycerides and enhanced clearance of triglyceride-rich lipoproteins from the bloodstream, resulting in reduced levels of triglycerides and, to a lesser extent, LDL cholesterol.
Mixed Dyslipidemia: Ciprofibrate may be used to treat mixed dyslipidemia, a condition characterized by elevated levels of both cholesterol and triglycerides in the blood. It can help improve the lipid profile by reducing triglyceride levels and increasing HDL cholesterol levels, leading to a decrease in the risk of cardiovascular events such as heart attacks and strokes.
Primary Prevention of Cardiovascular Disease: Ciprofibrate may be used as part of a comprehensive approach to reduce the risk of cardiovascular disease in individuals with dyslipidemia who have not yet experienced a cardiovascular event. By improving lipid parameters, particularly reducing triglycerides and increasing HDL cholesterol, ciprofibrate may help lower the risk of atherosclerosis and its complications.
Secondary Prevention of Cardiovascular Events: Ciprofibrate may also be used for secondary prevention in individuals with a history of cardiovascular events, such as myocardial infarction (heart attack) or stroke, who have persistent dyslipidemia despite lifestyle modifications and other interventions. By optimizing lipid levels, ciprofibrate may reduce the risk of recurrent cardiovascular events and improve overall prognosis.
Adverse Effects: Common side effects of ciprofibrate may include gastrointestinal disturbances (such as abdominal pain, nausea, diarrhea), muscle pain or weakness (myopathy), elevated liver enzymes, and, rarely, gallstones or pancreatitis. Patients taking ciprofibrate should be monitored regularly for signs of myopathy (e.g., unexplained muscle pain, tenderness, weakness) and liver function abnormalities.
Drug Interactions: Ciprofibrate may interact with other medications, particularly those metabolized by the cytochrome P450 system, such as statins (cholesterol-lowering drugs), anticoagulants (blood thinners), and certain antibiotics. Concurrent use of ciprofibrate with these medications may increase the risk of drug interactions and adverse effects, necessitating close monitoring and dose adjustments as needed.
Contraindications: Ciprofibrate is contraindicated in individuals with severe liver or kidney impairment, gallbladder disease, or a history of hypersensitivity to fibrates or any of the components of the medication. It should be used with caution in elderly patients and those with a history of myopathy or rhabdomyolysis (muscle breakdown).
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.6 | 0.1 | 5 |
| ADHD | 2.3 | 0.3 | 6.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 0.8 | 1.75 |
| Allergies | 3.1 | 1.5 | 1.07 |
| Allergy to milk products | 1.2 | 1.3 | -0.08 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 3.1 | 4.6 | -0.48 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.4 | 3 |
| Ankylosing spondylitis | 2.4 | 1.2 | 1 |
| Anorexia Nervosa | 0.7 | 2.1 | -2 |
| Antiphospholipid syndrome (APS) | 1.7 | 0.3 | 4.67 |
| Asthma | 2.5 | 1.1 | 1.27 |
| Atherosclerosis | 1.6 | 1.7 | -0.06 |
| Atrial fibrillation | 2 | 2.9 | -0.45 |
| Autism | 5.2 | 5.6 | -0.08 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 1.6 | 0.8 | 1 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 0.6 | 0.6 | |
| Carcinoma | 2.8 | 1.3 | 1.15 |
| Celiac Disease | 2.4 | 1.3 | 0.85 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 2 | 3.8 | -0.9 |
| Chronic Kidney Disease | 2.3 | 2.1 | 0.1 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.4 | 0 |
| Chronic Urticaria (Hives) | 1.2 | 1 | 0.2 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.8 | 1.13 |
| Cognitive Function | 1.8 | 1.1 | 0.64 |
| Colorectal Cancer | 4.5 | 2.1 | 1.14 |
| Constipation | 1.1 | 1 | 0.1 |
| Coronary artery disease | 2.4 | 2.5 | -0.04 |
| COVID-19 | 4.5 | 5.8 | -0.29 |
| Crohn's Disease | 5.4 | 3.5 | 0.54 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 1 | 0.8 | 0.25 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.2 | 1.1 | 1 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 4.9 | 5.8 | -0.18 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.8 | 0.7 | 1.57 |
| Endometriosis | 2.3 | 1.5 | 0.53 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.5 | 1.3 | 0.92 |
| erectile dysfunction | 1.8 | 1.8 | |
| Fibromyalgia | 1.5 | 1.7 | -0.13 |
| Functional constipation / chronic idiopathic constipation | 3.7 | 2.6 | 0.42 |
| gallstone disease (gsd) | 2.4 | 0.8 | 2 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.3 | 2 |
| Generalized anxiety disorder | 2.7 | 1.4 | 0.93 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 1 | 1.7 | -0.7 |
| Gulf War Syndrome | 0.6 | 0.9 | -0.5 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 1.6 | 0.6 | 1.67 |
| Heart Failure | 2.9 | 1.2 | 1.42 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.9 | 0.9 | |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.7 | |
| hyperglycemia | 1 | 0.7 | 0.43 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 2.5 | 2.9 | -0.16 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 1.7 | 0.6 | 1.83 |
| IgA nephropathy (IgAN) | 1.3 | 2.4 | -0.85 |
| Inflammatory Bowel Disease | 4.3 | 5.7 | -0.33 |
| Insomnia | 0.9 | 1.4 | -0.56 |
| Intelligence | 1.1 | 0.6 | 0.83 |
| Intracranial aneurysms | 1 | 0.6 | 0.67 |
| Irritable Bowel Syndrome | 4.1 | 2.5 | 0.64 |
| ischemic stroke | 1.4 | 1.7 | -0.21 |
| Liver Cirrhosis | 4.4 | 2.3 | 0.91 |
| Long COVID | 4.7 | 3.9 | 0.21 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 0.9 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 0.9 | -2 |
| ME/CFS without IBS | 0.9 | 0.3 | 2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 5.8 | 3.5 | 0.66 |
| Mood Disorders | 4.3 | 5.3 | -0.23 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 2.7 | 3.5 | -0.3 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 1.7 | -1.7 | |
| Neuropathy (all types) | 0.3 | 2.5 | -7.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 2.1 | 0.67 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 6.1 | 3.8 | 0.61 |
| obsessive-compulsive disorder | 2.8 | 2.7 | 0.04 |
| Osteoarthritis | 2 | 0.6 | 2.33 |
| Osteoporosis | 1.4 | 0.6 | 1.33 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 4.6 | 4.8 | -0.04 |
| Polycystic ovary syndrome | 4.5 | 1.7 | 1.65 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.4 | -0.33 |
| primary biliary cholangitis | 0.3 | 1.1 | -2.67 |
| Primary sclerosing cholangitis | 1.4 | 1.3 | 0.08 |
| Psoriasis | 1.5 | 2.8 | -0.87 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.7 | 3.1 | 0.52 |
| Rosacea | 0.1 | 0.5 | -4 |
| Schizophrenia | 2.6 | 1.6 | 0.63 |
| scoliosis | 0.7 | 0.3 | 1.33 |
| Sjögren syndrome | 2.2 | 1.2 | 0.83 |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 1.5 | |
| Stress / posttraumatic stress disorder | 1.9 | 1.8 | 0.06 |
| Systemic Lupus Erythematosus | 3.8 | 0.8 | 3.75 |
| Tic Disorder | 0.8 | 0.9 | -0.13 |
| Tourette syndrome | 0.3 | 0.3 | 0 |
| Type 1 Diabetes | 2.4 | 1.3 | 0.85 |
| Type 2 Diabetes | 6.2 | 4.2 | 0.48 |
| Ulcerative colitis | 2.6 | 4 | -0.54 |
| Unhealthy Ageing | 2.7 | 2.2 | 0.23 |
| Vitiligo | 1.4 | 1 | 0.4 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
